TEV-’408

July 7, 2026: Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA) said it plans to advance TEV-’408, an investigational anti-interleukin-15 (IL-15) monoclonal antibody, into a Phase 2b study in non-segmental vitiligo (NSV) in 4Q 2026, following encouraging results from an ongoing Phase 1b open-label study in adults with active or stable NSV.

At week 24 in evaluable participants, TEV-’408 showed improvements in skin pigmentation and was well-tolerated with no safety signals observed to date. Reported outcomes included: nearly 75% of patients reporting improvement in facial vitiligo (about half “much” or “very much” improved), 42% achieving F‑VASI50 and 21% achieving F‑VASI75; 55% reporting improvement in total body vitiligo, with 7% achieving T‑VASI50. The study enrolled patients with F‑VASI >0.5 or T‑VASI >5; dosing was two subcutaneous injections on Day 0 and week 12, with monitoring through week 80.

Teva also noted TEV-’408 is in a Phase 2a celiac disease study and received FDA Fast Track designation for celiac disease in May 2025. An investor call/webcast to discuss the data was scheduled for 8:00 a.m. ET on July 7, 2026 (the release also lists January 7, 2026).